CITY OF LONDON INVESTMENT GROUP

Similar documents
CITY OF LONDON INVESTMENT GROUP

BURFORD CAPITAL. Financial summary and valuation

City of London Investment Group

City of London Investment Group

GENEDRIVE PLC Preventing hearing loss in newborns

City of London Investment Group

Alliance Pharma. 2017: strong operational cashflow. Financial summary and valuation

City of London Investment Group*

Aberdeen Asset Management

Tissue Regenix. Full-year 2017: what to look for. Financial summary and valuation

Allergy Therapeutics

Key estimate revision. Financial summary. Year FY14 391,088 45,198 34, FY15E 354,262 35,426 23,

R e t r e a t s & R e c o v e r i e s. S a m S t o v a l l, J u l y 2 5,

Key estimate revision. Financial summary. Year

Adani Ports & SEZ Rating: Target price: EPS:

MCX Ltd. Rating: Target price: EPS: Tepid volume growth continues. Target. Rating CMP. Rs. 1,080 SELL. Rs. 1,176

ITC. Rating: Target price: EPS: Relative better visibility despite the smoke, Maintain BUY CMP. Target. Rating. Rs.389. Buy. Rs.

PPHE Hotel Group. Operating results in line. Financial summary and valuation

Burford Capital. Arbitration judgement shows value of patience. 24 th July 2017

CONSENSUS OPERATING EARNINGS for the S&P 500, MidCap 400 and SmallCap 600 Indices, as well as the Sectors in the S&P /02/18

ETFs: Regulatory (High) Impact. Commerzbank, leaders in ETF February 2018

3Q 30 SEPTEMBER 2018 MFS EUROPEAN EQUITY EX U.K. (USD)

Key estimate revision. Financial summary. Year FY16E 29, % 3,583 2, FY17E 26, % 3,478 2,

Financial summary. Year

Kalpataru Power. Rating: Target price: EPS: Rating CMP. Target BUY. Rs Rs.256

An Introduction to Exchange Traded Products

Results Presentation December 2013

QV Equities Limited. Investor Update - 1 -

Alliance Pharma. Financial summary and valuation

Key estimate revision. Financial summary. Year FY15 121, % 16, % FY16E 137, % 20,

Century Plyboards (India)

Key estimate revision. Financial summary. Year

MiFID II Monitor. Assessing the impact so far. Revisiting the issue of stock liquidity. August 2018

Century Plyboards (India)

Key estimate revision. Year CY14 87,383 11,148 6, CY15E 1,20,126 17,838 9,

Simmtech (222800) Focus on 2H earnings WHAT S THE STORY?

TSX COMPOSITE EARNINGS SCORECARD AGGREGATE EARNINGS AND REVENUE PERFORMANCE VS ESTIMATES

Key estimate revision. Year FY14 23,28,609 3,48,027 1,40, FY15E 25,74,029 3,94,133 1,69,

HCL Technologies. Rating: Target price: EPS: Target CMP. Rating. Rs. 826 REDUCE. Rs.760

EQUITY RESEARCH. Royal Dutch Shell B, Attractively Valued - Buy. Share Price: 2,202p Target Price: 2,500p (+14%) 21 September 2017

Larsen & Toubro Ltd.

Daewoo E&C ( KS) WHAT S THE STORY?

Dr Reddy s Laboratories

MCX Ltd. Rating: Target price: EPS: Is commodity option a game changer for MCX? - Unlikely. Target. Rating CMP. Rs. 1,080 SELL. Rs.

BANGO SOFTWARE AND COMPUTER SERVICES

Platinum Asset Management

Sector Methodology. Quality. Scale. Performance.

Polish Banks. Upgrading ratings for CHF exposed banks. Sector update. Banks Poland

Maruti Suzuki. Source: Company Data; PL Research

BUY Price at COB 1 October p 52-week range 39-68p. CSF Group CX6 restructuring. Technology.

Advanced Vision Techn Buy

Weekly 2018 Week 52 WEEK AHEAD. Market Research Czech Republic & Eurozone. December

AUSTRALIAN SECURITISATION FORUM Australian Market Review and Outlook. Ken Hanton May 2018

Ramco Cement. Rating: Target price: EPS: Rating CMP. Target BUY. Rs.415. Rs. 360

Crompton Greaves. Looking to exit overseas Power segment! Source: Company Data; PL Research

TTK Prestige. Channel-check takeaways Growth recovery pace sees moderation, competitive headwinds continue to prevail. Target CMP. Rating Rs.

Key estimate revision. Financial summary. Year

3Q 30 SEPTEMBER 2018 MFS U.K. EQUITY (USD)

PGCIL Order Inflow Analysis

Singapore Fixed Income Indices (SFI) Weekly

Near-term pressure, but long-term outlook positive

Derivatives Spot. Third round of LP restrictions making its mark. March 21, Overview

ISRA VISION Neutral

I n v e s t m e n t O u t l o o k S a m S t o v a l l, A p r i l 1 5,

LG International (001120) Poor 3Q expected to be just a blip WHAT S THE STORY? SUMMARY OF 3Q RESULTS

Bharat Forge. Result Update. Q4FY13 Result Highlights. Valuation. No Respite in Sight May 29, Institutional Research 1

DX (Group) plc* Industrial Transportation. Successful HMPO tender improves forecast certainty. Price 17.75p. Price Performance. Financial Forecasts

Rating Action: Moody's assigns A3 issuer rating to Nidec Corporation; outlook stable Global Credit Research - 31 Jan 2018

TVS Motors. Source: Company Data; PL Research

Year to PBT EPS DPS PER PEG Yield. January m P P x X % FY18a FY19e

Market Pulse. Inter. FFBL: Weak pricing power; Sell. Pakistan Fertilizer

Lonsec Diversified Direct Model Portfolios

IOOF. Positive flows in 1Q17. FUM and Net Flows for September Qtr Source: Company data, Macquarie Research, Oct 2016.

EQUITY RESEARCH. Reckitt Benckiser, French s Food business sold. Share Price: 7,936p Target Price: 8,000p* (+1%) 19 July 2017

Karur Vysya Bank (KVB) KVB IN; KVB.BO

Regional REIT. Asset growth and refinancing completed. Further portfolio growth and diversification. Acquisition benefit offset by underlying revision

HAEMATO AG SOLID UPTICK IN H2 SALES AND EBIT MARGIN. FIRST BERLIN Equity Research PRICE TARGET H A

PHOTO-ME SUPPORT SERVICES. Laundry Becoming more Material. Interim Results. 11 December 2017 PTHM.L

Colgate-Palmolive (India)

FLOW TRADERS REPORTS RESILIENT PERFORMANCE IN SLOW MARKET CONDITIONS

Earnings sustainability and asset quality remain under pressure

Interim Announcement Presentation

Falanx Group Ltd. 16 October


Jamna Auto Industries

Equitas Holdings. Rating: Target price: ABV: Target CMP. Rating. Rs Rs. 226 BUY

An introduction to Exchange Traded Products

1 November 2017 M1 Kliniken AG. FIRST BERLIN Equity Research. Update following

2Q 30 JUNE 2018 MFS GLOBAL EQUITY (AUD)

Rating Action: Moody's assigns (P)Ba2 ratings to Intrum Justitia AB; outlook positive Global Credit Research - 12 Jun 2017

Gillette India. Institutional Equities. 1QFY18 Result Update

Kuwait: Ready for a FTSE Upgrade?

Siemens. Railways and T&D driving inflows. Source: Company Data; PL Research

International Bank for Reconstruction and Development 'AAA/A-1+' Ratings Affirmed; Outlook Remains Stable

Ambuja Cements. Rating: Target price: EPS: Rating CMP. Target BUY. Rs.225. Rs. 195

ITC Ltd. BUY CMP (Rs.) 304 Target (Rs.) 336 Potential Upside(%) 11% Valuation: Investment Rationale. For private circulation only

2Q16 Highlights: 12M FWD EV/EBITDA 12M PRICE PERFORMANCE VS. IPC P/E

BUY CMP (Rs.) 297 Target (Rs.) 385 Potential Upside 30%

Balkrishna Industries

AMINO TECHNOLOGIES SOFTWARE AND COMPUTER SERVICES. FY 18E expectations confirmed. 17 July 2018 AMO.L

Transcription:

9 October 2018 Financial Services Daily CLIG.L Line, CLIG.L, Trade Price(Last), 09/10/2018, 409.00, N/A, N/A Market data Source: Eikon Thomson Reuters EPIC/TKR CLIG Price (p) 400.0 12m High (p) 454.0 12m Low (p) 366.0 Shares (m) 26.9 Mkt Cap ( m) 107.6 EV ( m) 87.9 Market LSE Description City of London is an investment manager specialising in using closedend funds to invest in emerging and other markets. Company information CEO CFO Chairman Key shareholders 26/04/2016-08/10/2018 (LON) Price GBp M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O Q2 16 Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Barry Olliff Tracy Rodrigues David Cardale +44 (0) 207 860 8346 www.citlon.com Directors & staff 16.3% Blackrock 9.9% Cannacord Genuity 7.9% Eschaton Opportunities Fund Management 4.7% Polar Capital 4.1% 450 440 430 420 409.00 410 400 390 380 370 360 350 340 330 320 310 300 290 Auto CITY OF LONDON INVESTMENT GROUP Solid FUM update offset by margin changes City of London has released its trading update for 1Q of FY 19. The statement shows a continuation of the trends seen in recent statements. Aggregate inflows into the newer strategies were largely offset by rebalancing outflows from the Emerging Markets strategy, resulting in a small amount of net inflows of $8m. Market movements were mixed, with only developed markets rising during the quarter and MSCI EM index declining 1%. Fund performance was slightly behind benchmarks, with manager performance and widening discounts hampering different strategies. In aggregate, FUM declined slightly from $5.11bn to $5.01bn. Operations: The changing mix of the assets continues to affect the revenue margin. Both Developed Markets and Opportunistic Value are lower margin than the existing Emerging Market business. Their rising proportion led to a decline in revenue margin to 77bps, from the 80bps previously indicated. Costs: The costs were largely in line with those indicated at the time of the fullyear results. The EIP charge has increased a little, to 4% from the 3% at the fullyear results. Estimated earnings for the first quarter will be 2.2m, down from the previous year s figure of 2.5m. Valuation: The prospective P/E of 11.2x is at a significant discount to the peer group. The historical yield of 6.8% is attractive and should, at the very least, provide support for the shares in the current markets. Risks: Although emerging markets can be volatile, City of London has proved to be more robust than some other EM fund managers, aided by its good performance and strong client servicing. Further EM volatility could increase the risk of such outflows, although increased diversification is also mitigating this. Investment summary: Having shown robust performance in challenging market conditions, City of London is now reaping the benefits in a more supportive environment. The valuation remains reasonable. FY 17 and FY 18 both saw dividend increases and, unless there is significant market disruption, more should follow in the next few years. Diary 11 Oct Ex-div. date for final dividend 22 Oct AGM 16 Jan 2Q FUM announcement 18 Feb Half year results Analyst Brian Moretta 020 7194 7622 bm@hardmanandco.com Financial summary and valuation Year-end Jun ( m) FUM ($bn) 4.20 4.00 4.66 5.11 5.29 5.69 Revenue 25.36 24.41 31.29 33.93 31.95 33.30 Statutory PTP 8.93 7.97 11.59 12.79 11.27 11.91 Statutory EPS (p) 26.4 23.3 36.9 39.5 35.8 37.8 Dividend (p) 24.0 24.0 25.0 27.0 30.0 33.0 P/E (x) 15.2 17.2 10.8 10.1 11.2 10.6 Yield 6.0% 6.0% 6.3% 6.8% 7.5% 8.3% Source: Hardman & Co Research Disclaimer: Attention of readers is drawn to important disclaimers printed at the end of this document

Funds under management ($bn) 6.0 5.0 4.0 3.0 2.0 1.0 Net inflows since 2014 Market weakness in 2016 substantially offset by new business flows Assumed steady new business flows and market growth of 5% p.a. 0.0 Revenue 40 35 Revenue strongly linked to FUM m 30 25 20 Ongoing decrease in revenue margins from new business Some currency effects, particularly from a strong US dollar between 2015 and 2017 15 10 2019E growth affected by reduction of revenue margins 5 0 EPS (bar) and dividend (line) 50 40 30 Profitability historically maintained by cost flexibility Currency movements led to step change in 2017 EPS Dividend shortfall in 2016 covered from reserves (p) 20 Dividend increased in 2017 and 2018 we expect steady increases in the dividend over the next couple of years 10 0 Source: Company data; Hardman & Co Research 9 October 2018 2

Commentary Funds under management ($m) Sep 2018 Jun 2018 Net flows Other movements Emerging Markets 4,016 4,207-95 -96 Developed Markets 577 481 98-2 Frontier Markets 215 245-21 -9 Opportunistic Value 200 174 26 0 Total 5,008 5,107 8-107 Source: Hardman & Co Research The figures for fund flows were somewhat mixed, although largely following the trends seen in recent statements. In particular, the newer diversifying strategies of Developed Markets and Opportunistic Value saw net inflows of assets. Figures for the latter include a new Municipal Bond mandate. As seen recently, offsetting these were rebalancing outflows in Emerging Markets, although this quarter also saw rebalancing of some Frontier Market and Opportunistic Value assets too. The net effect was an aggregate new inflow of $8m of FUM. Market movements were mostly unfavourable, with only the developed market benchmark rising. This rise was offset in City of London s funds by widening discounts. In Emerging and Frontier Markets, the NAV performance of the underlying managers was weak. Overall performance was slightly behind benchmarks. Estimate updates Hardman & Co has made three main adjustments to its estimates in light of the latest statement. The largest is the rate of decline of the revenue margin. This is proceeding quicker than previously assumed, with the 77bps rate lower than our assumption for the end of FY 20. As well as moving the current rate down to the new level, a more aggressive future decline is now assumed. FUM were lower than our estimates, and this has had an effect. Hardman & Co had been assuming a small net inflow for EM assets. Given the ongoing rebalancing does not appear to have been slowed by emerging market weakness, we have reduced this to zero. A small adjustment has also been made to the rate of accrual of the EIP, which has ticked up compared with previously. The net effect is that the Hardman & Co 2019E EPS has declined from 41.8p to 35.8p and 2020 estimate from 45.3p to 37.8p. 9 October 2018 3

Financials Summary financials Year-end June FUM ($bn) 4.20 4.00 4.66 5.11 5.29 5.69 P&L ( m) Revenue 25.36 24.41 31.29 33.93 31.95 33.30 Expenses 16.63 16.66 19.79 21.40 20.70 21.40 Operating profit 8.73 7.76 11.51 12.53 11.26 11.90 PBT 8.93 7.97 11.59 12.79 11.27 11.91 Earnings 6.61 5.85 9.14 10.06 8.90 9.41 EPS (p) 26.4 23.3 36.9 39.5 35.8 37.8 DPS (p) 24.0 24.0 25.0 27.0 30.0 33.0 Key metrics Growth (%) FUM 7.7-4.8 16.5 9.6 3.6 7.5 Revenue 4.7-3.7 28.2 8.4-5.8 4.2 Operating Profit 24.7-11.1 48.4 8.8-10.1 5.7 EPS 27.5-11.7 58.4 7.0-9.4 5.7 DPS 0.0 0.0 4.2 8.0 11.1 10.0 Operating margins (%) Net FUM fee margin 0.86 0.86 0.84 0.80 0.77 0.76 Operating margin 34.4 31.8 36.8 36.9 35.2 35.7 Tax rate 26.0 26.5 21.1 21.0 21.0 21.0 Dividend cover(x) 1.1 1.0 1.5 1.5 1.2 1.1 EPS Sensitivity No net new business eps (p) 35.4 36.4 change -1.0% -3.8% 0% market growth (was 5% pa) eps (p) 34.9 33.9 change -2.4% -10.3% Source: City of London Investment Group, Hardman & Co Research 1=$1.31 9 October 2018 4

Disclaimer Hardman & Co provides professional independent research services and all information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable. However, no guarantee, warranty or representation, express or implied, can be given by Hardman & Co as to the accuracy, adequacy or completeness of the information contained in this research and they are not responsible for any errors or omissions or results obtained from use of such information. Neither Hardman & Co, nor any affiliates, officers, directors or employees accept any liability or responsibility in respect of the information which is subject to change without notice and may only be correct at the stated date of their issue, except in the case of gross negligence, fraud or wilful misconduct. In no event will Hardman & Co, its affiliates or any such parties be liable to you for any direct, special, indirect, consequential, incidental damages or any other damages of any kind even if Hardman & Co has been advised of the possibility thereof. This research has been prepared purely for information purposes, and nothing in this report should be construed as an offer, or the solicitation of an offer, to buy or sell any security, product, service or investment. The research reflects the objective views of the analyst(s) named on the front page and does not constitute investment advice. However, the companies or legal entities covered in this research may pay us a fixed fee in order for this research to be made available. A full list of companies or legal entities that have paid us for coverage within the past 12 months can be viewed at http://www.hardmanandco.com/legals/researchdisclosures. Hardman may provide other investment banking services to the companies or legal entities mentioned in this report. Hardman & Co has a personal dealing policy which restricts staff and consultants dealing in shares, bonds or other related instruments of companies or legal entities which pay Hardman & Co for any services, including research. No Hardman & Co staff, consultants or officers are employed or engaged by the companies or legal entities covered by this document in any capacity other than through Hardman & Co. Hardman & Co does not buy or sell shares, either for their own account or for other parties and neither do they undertake investment business. We may provide investment banking services to corporate clients. Hardman & Co does not make recommendations. Accordingly, they do not publish records of their past recommendations. Where a Fair Value price is given in a research note, such as a DCF or peer comparison, this is the theoretical result of a study of a range of possible outcomes, and not a forecast of a likely share price. Hardman & Co may publish further notes on these securities, companies and legal entities but has no scheduled commitment and may cease to follow these securities, companies and legal entities without notice. The information provided in this document is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Hardman & Co or its affiliates to any registration requirement within such jurisdiction or country. Some or all alternative investments may not be suitable for certain investors. Investments in small and mid-cap corporations and foreign entities are speculative and involve a high degree of risk. An investor could lose all or a substantial amount of his or her investment. Investments may be leveraged and performance may be volatile; they may have high fees and expenses that reduce returns. Securities or legal entities mentioned in this document may not be suitable or appropriate for all investors. Where this document refers to a particular tax treatment, the tax treatment will depend on each investor s particular circumstances and may be subject to future change. Each investor s particular needs, investment objectives and financial situation were not taken into account in the preparation of this document and the material contained herein. Each investor must make his or her own independent decisions and obtain their own independent advice regarding any information, projects, securities, tax treatment or financial instruments mentioned herein. The fact that Hardman & Co has made available through this document various information constitutes neither a recommendation to enter into a particular transaction nor a representation that any financial instrument is suitable or appropriate for you. Each investor should consider whether an investment strategy of the purchase or sale of any product or security is appropriate for them in the light of their investment needs, objectives and financial circumstances. This document constitutes a financial promotion for the purposes of section 21 Financial Services and Markets Act 2000 (United Kingdom) ( FSMA ) and accordingly has been approved by Capital Markets Strategy Ltd which is authorised and regulated by the Financial Conduct Authority (FCA). No part of this document may be reproduced, stored in a retrieval system or transmitted in any form or by any means, mechanical, photocopying, recording or otherwise, without prior permission from Hardman & Co. By accepting this document, the recipient agrees to be bound by the limitations set out in this notice. This notice shall be governed and construed in accordance with English law. Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the FCA under registration number 600843. Hardman Research Ltd is registered at Companies House with number 8256259. (Disclaimer Version 8 Effective from August 2018) Status of Hardman & Co s research under MiFID II Some professional investors, who are subject to the new MiFID II rules from 3rd January, may be unclear about the status of Hardman & Co research and, specifically, whether it can be accepted without a commercial arrangement. Hardman & Co s research is paid for by the companies, legal entities and issuers about which we write and, as such, falls within the scope of minor non-monetary benefits, as defined in the Markets in Financial Instruments Directive II. In particular, Article 12(3) of the Directive states: The following benefits shall qualify as acceptable minor non-monetary benefits only if they are: (b) written material from a third party that is commissioned and paid for by a corporate issuer or potential issuer to promote a new issuance by the company, or where the third party firm is contractually engaged and paid by the issuer to produce such material on an ongoing basis, provided that the relationship is clearly disclosed in the material and that the material is made available at the same time to any investment firms wishing to receive it or to the general public The fact that Hardman & Co is commissioned to write the research is disclosed in the disclaimer, and the research is widely available. The full detail is on page 26 of the full directive, which can be accessed here: http://ec.europa.eu/finance/docs/level-2-measures/mifid-delegated-regulation- 2016-2031.pdf In addition, it should be noted that MiFID II s main aim is to ensure transparency in the relationship between fund managers and brokers/suppliers, and eliminate what is termed inducement, whereby free research is provided to fund managers to encourage them to deal with the broker. Hardman & Co is not inducing the reader of our research to trade through us, since we do not deal in any security or legal entity. 9 October 2018 5

research@hardmanandco.com 35 New Broad Street London EC2M 1NH www.hardmanandco.com +44(0)20 7194 7622